COG AALL0232: Lymphoblastic Leukemia

COG AALL0232: High Risk B-Precursor Acute Lymphoblastic Leukemia

Approval Date: 12/29/2003

Principal Investigator: Charles Main, MD

To increase the cure rate of children with high- risk ALL without increasing the side effects of therapy, by determining the safety and efficacy of different drugs during the course of treatment.

Eligibility:
Each study has its own guidelines for who can participate, called 'eligibility criteria'. Below is a partial list of criteria for acceptance into the research study. Only the study doctor can make the determination that you meet all eligibility criteria.

• Age 1-10 years: WBC >50,000
• Age > 10 years: any WBC
• Previously enrolled on AALL03B1
• Newly diagnosed B-precursor ALL
• No prior cytotoxic therapy

Contact Person:
Royal Oak
248-551-3230

Status of Clinical Trial:
open and enrolling